Avadel Pharmaceuticals plc (NASDAQ:AVDL) CEO Gregory J. Divis Buys 9,598 Shares

Avadel Pharmaceuticals plc (NASDAQ:AVDL) CEO Gregory J. Divis bought 9,598 shares of the business’s stock in a transaction dated Friday, December 6th. The shares were bought at an average price of $9.98 per share, with a total value of $95,788.04. Following the completion of the transaction, the chief executive officer now owns 9,598 shares in the company, valued at approximately $95,788.04. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Avadel Pharmaceuticals Stock Down 1.5 %

Shares of AVDL opened at $10.00 on Wednesday. Avadel Pharmaceuticals plc has a 12-month low of $9.41 and a 12-month high of $19.09. The business has a 50-day simple moving average of $12.58 and a two-hundred day simple moving average of $14.28. The stock has a market cap of $963.60 million, a PE ratio of -12.66 and a beta of 1.32.

Avadel Pharmaceuticals (NASDAQ:AVDL) last issued its earnings results on Tuesday, November 12th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.03. Avadel Pharmaceuticals had a negative return on equity of 93.34% and a negative net margin of 52.53%. The business had revenue of $50.00 million during the quarter, compared to analysts’ expectations of $48.43 million. During the same quarter in the prior year, the firm earned ($0.41) EPS. The business’s revenue for the quarter was up 624.6% compared to the same quarter last year. On average, equities research analysts expect that Avadel Pharmaceuticals plc will post -0.48 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Oppenheimer upped their price objective on Avadel Pharmaceuticals from $29.00 to $30.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. HC Wainwright dropped their price objective on Avadel Pharmaceuticals from $27.00 to $25.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. Finally, Needham & Company LLC restated a “buy” rating and set a $22.00 price objective on shares of Avadel Pharmaceuticals in a research report on Tuesday, November 12th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $24.43.

Hedge Funds Weigh In On Avadel Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of AVDL. FMR LLC acquired a new position in Avadel Pharmaceuticals in the 3rd quarter worth about $31,000. Amalgamated Bank acquired a new stake in shares of Avadel Pharmaceuticals in the second quarter valued at about $45,000. Quarry LP acquired a new stake in shares of Avadel Pharmaceuticals in the second quarter valued at about $63,000. Advisors Asset Management Inc. increased its stake in shares of Avadel Pharmaceuticals by 56.1% in the third quarter. Advisors Asset Management Inc. now owns 7,921 shares of the company’s stock valued at $104,000 after buying an additional 2,846 shares during the period. Finally, Beverly Hills Private Wealth LLC acquired a new stake in shares of Avadel Pharmaceuticals in the second quarter valued at about $146,000. Institutional investors and hedge funds own 69.19% of the company’s stock.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.